Kanechi Reo, Shishido Tatsuya, Tachikawa Mana, Nishimura Tomohiro, Sawada Akihito, Okade Hayato, Ishikawa Daisuke, Yamaguchi Hitoshi, Araki Marito
Drug Discovery Department, R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16 Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan.
Research Department, Research & Development Division, KM Biologics Co., Ltd., Kikuchi Research Center, 1314-1 Kyokushi Kawabe, Kikuchi-shi, Kumamoto, 869-1298, Japan.
Biochem Biophys Rep. 2025 Apr 2;42:101999. doi: 10.1016/j.bbrep.2025.101999. eCollection 2025 Jun.
ARCT-154, a recently approved self-amplifying mRNA (saRNA) vaccine for SARS-CoV-2, has shown superior induction and prolonged maintenance of neutralizing antibodies compared to the conventional mRNA vaccine BNT162b2. However, the scientific evidence explaining this superiority remained elusive. Hence, we explored the temporal changes in spike protein and replicase components following a single dose of ARCT-154 vaccination in mice. The encoded spike protein reached its highest level approximately 3 days after vaccination and quickly disappeared from the rectus femoris muscle, the injection site. Although the spike protein levels also peaked at an early time point in the lymph nodes, it remained detectable 28 days after the vaccination and then disappeared by 44 days after the vaccination. Expression of nsP1, nsP2 and nsP4 was observed in the injected muscle and/or the lymph nodes for up to 15 days post-vaccination. Data were analyzed using unpaired two-tailed Mann-Whitney U-tests. These data suggest that prolonged expression of spike proteins in lymph nodes may, if not entirely, be responsible for the induction of higher and prolonged levels of neutralizing antibodies by the saRNA vaccine.
ARCT-154是一种最近获批用于新型冠状病毒(SARS-CoV-2)的自扩增信使核糖核酸(saRNA)疫苗,与传统信使核糖核酸疫苗BNT162b2相比,它在诱导中和抗体方面表现出优势,且能使中和抗体维持更长时间。然而,解释这种优势的科学证据仍然难以捉摸。因此,我们探究了小鼠单次接种ARCT-154疫苗后刺突蛋白和复制酶成分随时间的变化。编码的刺突蛋白在接种疫苗后约3天达到最高水平,并迅速从注射部位股直肌中消失。尽管刺突蛋白水平在淋巴结中也在早期达到峰值,但在接种疫苗后28天仍可检测到,然后在接种疫苗后44天消失。接种疫苗后长达15天,在注射的肌肉和/或淋巴结中观察到非结构蛋白1(nsP1)、非结构蛋白2(nsP2)和非结构蛋白4(nsP4)的表达。数据采用非配对双尾曼-惠特尼U检验进行分析。这些数据表明,刺突蛋白在淋巴结中的长时间表达可能(即便不是完全)是saRNA疫苗诱导产生更高水平且维持时间更长的中和抗体的原因。